Home

Articles from GenSight Biologics S.A.

GenSight Biologics Announces the Filing of its 2024 Universal Registration Document
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · April 8, 2025
GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · February 27, 2025
GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · January 15, 2025
GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · December 18, 2024
GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · November 13, 2024
GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · October 28, 2024
GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · October 24, 2024
GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · September 23, 2024
GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · July 23, 2024
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · June 20, 2024
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · April 4, 2024
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · March 22, 2024
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · March 12, 2024
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · March 6, 2024
GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · March 15, 2023
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · March 13, 2023
GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · March 9, 2023
GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · May 19, 2022
GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · January 24, 2022
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · December 14, 2021
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · November 30, 2021
GenSight Biologics Announces the Publication of a Review of Gene Therapy Trials for LHON in International Ophthalmology Clinics
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · October 6, 2021
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
Regulatory News:
By GenSight Biologics S.A. · Via Business Wire · September 9, 2021